MindBio Therapeutics Corp. announced first doses have been administered in MindBio's Phase 2B clinical trial in patients with late-stage cancer. This Phase 2B randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of Lysergic Acid Diethylamide (LSD) MB22001 and Meaning Centred Psychotherapy is a world's first with take home approvals in cancer patients involving a total of 40 participants.

Patients with a stage IV solid tumour cancer and experiencing emotional distress are randomized into the trial.aning Centred Psychotherapy is a well-established psychotherapeutic intervention in advanced cancer patients with symptoms of anxiety and or depression. Patients with cancer often develop ongoing, clinically significant, symptoms of psychological distress. Depression is itself an independent risk factor of early death in cancer patients.

The efficacy of standard treatment approaches to anxiety and depression in cancer patients is mixed. The onset of clinical improvement with anti-depressants in cancer is delayed, relapse rates are high, and significant side effects compromise treatment adherence. LD-Microdosing data from a Phase 1 clinical trial in 80 healthy individuals showed increases in energy, social connectivity, creativity, wellness and happiness and that MB22001 is very well tolerated.

MB22001 is a proprietary, titratable form of LSD for take-home microdosing, a drug and treatment protocol primarily designed to target depressive symptoms. MindBio now has two Phase 2 clinical trials underway: 1) Phase 2A LSD-Microdosing (MB22001) in patients with Major Depressive Disorder, and; 2) Phase 2B LSD-Microdosing (MB22001) in patients with late stage Cancer.